Eric Jonasch, MD - The Clinical Implications of Current Treatment Options for von Hippel-Lindau Disease

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Danny Parkins sounds off on discourse surrounding Caleb Williams' injury (Hour 2) 40 min · 24 Sep 2026 · Rahimi & Grote Show

Cubs squander chance to clinch playoff berth in losing to Marlins, 3-2 (Hour 1) 42 min · 24 Sep 2026 · Rahimi & Grote Show

Danny Parkins sounds off on discourse surrounding Caleb Williams' injury 19 min · 24 Sep 2026 · Rahimi & Grote Show

710: That New Mouse Pad Feeling 2h 13m · 24 Sep 2026 · Accidental Tech Podcast

Steven Bartlett REVEALS the Secret Behind the World’s Fastest Growing Podcast | PBD Podcast #861 1h 27m · 24 Sep 2026 · PBD Podcast

1PM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

Report any issue

Source

Recorded07 Nov 2022

Publisherc.answersincme.com ↗

Handlerec:766102

Show notes

Please visit answersincme.com/EZF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the current treatment options for von Hippel-Lindau (VHL) disease. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the management of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC); Describe the clinical impact of current guideline-recommended treatment options for VHL-associated RCC; and Identify strategies to manage adverse events arising from systemic treatment options for VHL-associated RCC.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in